patent for semaglutide expires next year: Novo Nordisk faces tough competition in the Chinese obesity market Semaglutide Patent Expiry in 2026:
Description
Large analyses have not confirmed higher pancreatic or thyroid cancer risk, but labels still carry warnings
Its receptor binding profile shows that it binds to GIP receptors with an affinity similar to the natural hormone but has a fivefold lower affinity for GLP-1 receptors
Among patients who discontinued, the cumulative incidence of treatment reinitiation was 41.1% at 1 year and 57.4% at 3 years after discontinuation
PROMOTE HEALTHY FAT LOSS
Once-Daily Dosing: Simplifies treatment with easy-to-follow dosing schedules, improving compliance
